Bullish
Eli Lilly's stock hits all-time high after EMA recommends Jaypirca for CLL treatment.
Eli Lilly's stock reached an all-time high following the European Medicines Agency's (EMA) advisory committee recommendation to approve Jaypirca (pirtobrutinib) for treating adults with chronic lymphocytic leukemia (CLL) across all lines of therapy. Additionally, the availability of Lilly's obesity drugs, Zepbound and Foundayo, through Medicare at $50 per month starting July 1, 2026, further bolstered investor confidence.
Key points
- EMA advisory committee recommends approval of Jaypirca for CLL treatment.
- Zepbound and Foundayo to be available via Medicare at $50/month starting July 1, 2026.
- No significant market-moving news in the past 24 hours.
Sources
AI-generated from public news sources. Not financial advice.
